Developer docs
API playgroundTry for free, no card

Search company profiles

Wellysis

Full company profile

uuid0009ikj

Namestring
Wellysis
Legal namestring
주식회사 웰리시스 (Wellysis Corp.)
Websiteurl
wellysis.com
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable ECG monitoring, cardiac monitoring devices, AI ECG analysis, digital health platforms, medical device software
Industry4 codes
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAFAF
Wearables & Consumer IoT Integration Platforms (BYOD)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Wearable ECG Monitoring Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1S-Patch Hardware Sales
TypeHardware Sales
Description

Sale of wearable ECG patch devices (S-Patch Ex, S-Patch ExL) and accessories (electrodes, batteries). Reusable device with consumable electrodes and batteries.

wellysis.com
2Software/SaaS Subscriptions
TypeSubscription Recurring
Description

S-Patch App subscriptions, S-Patch Web platform access, and analysis services for healthcare providers. Cloud-based data processing and AI analysis services.

wellysis.com
3Analysis Services
TypeProfessional Services
Description

Professional ECG analysis services for clinics and screening centers. Includes physician report generation and clinical consultation support.

wellysis.com
4AI Algorithm Licensing
TypeLicensing Royalties
Description

Integration of Wellysis AI algorithms (DeepRhythmAI) with partner platforms. Revenue from algorithm licensing and integration partnerships.

wellysis.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1B2B Enterprise Pricing - Medical Institutions
ModelOtherBilling cadenceMulti-year contract
Notes

S-Patch is a medical device prescribed by hospitals. For hospital inquiries and purchasing, contact info@wellysis.com. Research and clinical trial pricing negotiated separately.

wellysis.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1S-Patch
Description

Flagship wearable ECG monitoring device line including S-Patch Ex (up to 3 days) and S-Patch ExL (up to 11-14 days) models, powered by Samsung Smart Health Processor.

wellysis.com
+3 more records
Core offering1 text field

Wellysis develops and sells the S-Patch, a lightweight (8.5–11g), reusable, waterproof wearable patch-type ECG monitor powered by Samsung's Smart Health Processor, capable of continuous ECG recording for up to 14 days. The device feeds a companion mobile app (S-Patch App), a cloud-based physician reading platform (S-Patch Web), and an AI-powered ECG analysis service (S-Patch AI / ECG Lakehouse) trained on more than 6 billion labeled heartbeats from 790+ healthcare providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Detection rate increases to over 80% in 7 days vs 30% in 24 hours for traditional Holter
+2 more records
Product overview1 text field

Wellysis offers a unified S-Patch ECG monitoring solution consisting of wearable patch devices (S-Patch Wear - including Ex, ExL, and Cardio models), companion mobile apps (S-Patch App for patient and S-Patch Medi for healthcare providers), a cloud-based web analysis platform (S-Patch Web), and AI-powered analytics (S-Patch AI/ECG Lakehouse). The product suite enables end-to-end ECG testing: patients wear the lightweight patch for 1-14 days, data syncs via Bluetooth to mobile devices and uploads to cloud, AI algorithms perform initial analysis, and physicians review/edit reports via web portal. Upcoming BioArmour extends the platform to multi-biosignal monitoring for high-risk occupations.

Product and service6 records
1S-Patch Wear (Ex and ExL models)
CategoryWearable ECG Hardware
Description

Wearable patch-type ECG monitoring device powered by Samsung Smart Health Processor. Two models: S-Patch Ex (up to 100 hours / 1–3 days) and S-Patch ExL (up to 264 hours / 3–11 days, FDA cleared for up to 14 days). Weighs 8.5–11g, IP55 waterproof, reusable with replaceable electrodes and coin-cell batteries, Bluetooth BLE 5.1 connectivity. Sold as a medical device prescribed by hospitals to clinics, hospitals, screening centers, CROs, and corporate wellness programs.

2S-Patch App (Ex)
CategoryMobile ECG Application
Description

Patient-facing mobile application (iOS and Android) paired with S-Patch Wear. Provides real-time ECG waveform display, live HR and HRV monitoring, symptom and activity diary, and automatic encrypted upload of ECG data to the cloud server upon test completion. Targets patients prescribed the S-Patch Ex wearable.

3S-Patch App (Medi)
CategoryClinical Mobile Application
Description

Healthcare professional mobile application for managing S-Patch tests without requiring the patient's smartphone. Supports multiple simultaneous patient tests, device management, live ECG monitoring, battery level tracking, and scheduled data uploads. Used by clinicians and clinical staff in hospitals, clinics, and screening centers.

4S-Patch Web
CategoryCloud ECG Analysis Platform
Description

Cloud-based ECG reading and analysis web platform for physicians and clinical staff. Features test management, ECG data review with AI pre-analysis, and report generation (Physician Report, Screening Report, Full Disclosure Report) delivered as PDF documents. Sold as a subscription/SaaS service to clinics, hospitals, and screening centers, with optional professional ECG analysis services.

5S-Patch AI (ECG Lakehouse)
CategoryAI ECG Analytics Service
Description

AI-powered ECG analysis service backed by the ECG Lakehouse deep neural network platform trained on 6B+ labeled heartbeats from 1.5M+ hours of continuous ECG across 790+ healthcare providers. Capabilities include arrhythmia diagnosis, ECG clinical reports, HRV-based stress scoring, posture analysis, activity tracking, fall detection, and atrial fibrillation prediction. Delivered as an add-on analysis service for clinical customers and licensed to partner platforms (e.g., Medicalgorithmics DeepRhythmAI).

6BioArmour
CategoryMulti-Biosignal Wearable
Description

Next-generation wearable solution for frontline responders (firefighters, police, military, coast guards) and high-performance athletes. AI-powered multi-biosignal analysis monitoring ECG, core body temperature, body composition, and motion for early detection of abnormal signs. Multiple form factors with high durability for high-risk frontline and athletic environments. Unveiled at CES 2026 and targeted at public safety agencies and defense organizations.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-14
Description

Strategic partnership with Poland-based AI-driven cardiac diagnostics company. Wellysis integrates FDA-cleared S-Patch with Medicalgorithmics' DeepRhythm Platform (DRP) and DeepRhythmAI (DRAI) algorithms for more precise, real-time patient data analysis. Expected to enhance product capabilities and support global customer expansion.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-28
Description

Exclusive partnership for clinical trials. HeartcoR Solutions, a leading ECG core lab for pharmaceutical and medical device cardiac safety studies, has exclusive rights to offer S-Patch device in global clinical trials. Supports decentralized clinical trials with easy-to-use wearable ECG technology.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-03-08
Description

Partnership for US remote cardiac monitoring service launch. Artella provides comprehensive remote cardiac monitoring across 10 US states. Combined offering includes Samsung smartphones/smartwatches integration with S-Patch ExL. Starting in Texas with expansion plans.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-15
Description

Business collaboration with Samsung Electronics' System LSI division for next-generation S-Patch development. Joint development agreement for wearable biosignal measurement devices using Samsung's Smart Health Processor. Includes monitoring services for high-risk occupations and corporate wellness programs.

5Kangbuk Samsung Hospital
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-10-20
Description

Corporate cardiovascular disease prevention program with Kangbuk Samsung Hospital and Samsung Electronics. Provides full-covered health management services within workplace using S-Patch ECG tests for Samsung DS employees.

wellysis.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-10-01
Description

Partnership with India's prominent bed monitoring solutions provider. S-Patch devices to be integrated into 50,000 of Dozee's hospital beds starting January 2024, following successful product launch event in New Delhi.

7Samjin Pharmaceutical Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-10-20
Description

Exclusive distributor and investment contract. Samjin Pharmaceutical distributes S-Patch Cardio in Korean domestic market. Partnership enables wide distribution from primary care clinics to tertiary hospitals.

wellysis.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-06-01
Description

Research collaboration for COVID-19 wearable project monitoring recovered patients. Stanford uses S-Patch Cardio in project involving 1,000 recovered COVID-19 patients to study cardiovascular health impacts.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-09-01
Description

Joint development MOU signed for cardiac monitoring solutions. Apollo operates 40+ heart disease centers across India. Partnership for market expansion in India.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Eko develops AI-powered digital stethoscopes with ECG and cardiac auscultation analysis, including SENSORA cardiac AI platform. Comparable to Wellysis in AI-driven cardiac diagnostics and expanding into multi-biosignal wearables for clinicians.

TypeDirect peer
Description

VivaLNK makes wearable ECG patches and connected health sensors for remote patient monitoring. Direct comparable to S-Patch in form factor and continuous monitoring use cases, also serving clinical trial and RPM customers. (Also notable as the prior employer of Wellysis's CCO.)

TypeDirect peer
Description

Medicalgorithmics is a Poland-based cardiac diagnostics AI company offering DeepRhythm Platform (DRP) and DeepRhythmAI algorithms. Already a strategic integration partner of Wellysis, with overlapping AI ECG analysis capabilities and customer base in pharma clinical trials.

TypeBroad incumbent
Description

Apple Watch offers single-lead ECG with FDA-cleared AF detection for consumer use. A broad incumbent shaping consumer expectations around wearable ECG and indirectly competing for cardiac monitoring mindshare, though limited to consumer/wrist-based form factor.

TypeBroad incumbent
Description

Boston Scientific acquired Preventice Solutions, which offers BodyGuardian remote cardiac monitoring. A larger incumbent with established US sales infrastructure, deep reimbursement, and broader cardiology device portfolio competing for hospital accounts.

TypeDirect peer
Description

AliveCor's KardiaMobile is a single/6-lead ECG device for consumer and clinical AF detection, with AI-based interpretation. Competes with Wellysis in clinical-grade ECG AI and offers an alternative delivery model (handheld vs patch).

TypeBroad incumbent
Description

Philips acquired BioTelemetry, one of the largest US ambulatory cardiac monitoring providers (MCOT, Holter). A broad incumbent offering overlapping remote cardiac monitoring and AI analysis services to Wellysis's target hospital segment.

TypeEmerging player
Description

Dozee is India's leading bed-based contactless patient monitoring company, integrating Wellysis S-Patch into 50,000 hospital beds. Comparable in remote patient monitoring for hospital inpatients, focused primarily on South Asia with growing international expansion.

TypeRegional player
Description

HeartcoR is a US-based ECG core lab focused on cardiac safety studies for pharma and medical device clinical trials. Exclusive channel partner of Wellysis for clinical trials; comparable in cardiac clinical services but serving a different primary customer segment (CROs vs hospitals).

TypeDirect peer
Description

iRhythm is the leading US patch-based cardiac monitor (Zio) with strong CMS reimbursement and a deep clinical evidence base. Direct competitor to Wellysis's S-Patch in the ambulatory ECG monitoring segment, with overlap in arrhythmia detection AI and enterprise hospital sales motion.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wellysis

Wearable ECG Monitoring Deviceswellysis.com

Wellysis firmographics

Firmographics
Name
Wellysis
Legal name
주식회사 웰리시스 (Wellysis Corp.)
Website
https://wellysis.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Wellysis industry classification

Industry
Product category
Wearable ECG Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAFAF
Wearables & Consumer IoT Integration Platforms (BYOD)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Wearable ECG monitoring
  • Cardiac monitoring devices
  • AI ECG analysis
  • Digital health platforms
  • Medical device software

Where Wellysis is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Wellysis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. S-Patch Hardware Sales: Sale of wearable ECG patch devices (S-Patch Ex, S-Patch ExL) and accessories (electrodes, batteries). Reusable device with consumable electrodes and batteries.
  2. Software/SaaS Subscriptions: S-Patch App subscriptions, S-Patch Web platform access, and analysis services for healthcare providers. Cloud-based data processing and AI analysis services.
  3. Analysis Services: Professional ECG analysis services for clinics and screening centers. Includes physician report generation and clinical consultation support.
  4. AI Algorithm Licensing: Integration of Wellysis AI algorithms (DeepRhythmAI) with partner platforms. Revenue from algorithm licensing and integration partnerships.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B Enterprise Pricing - Medical Institutions

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Wellysis product offering

Product offering

Core offering

Wellysis develops and sells the S-Patch, a lightweight (8.5–11g), reusable, waterproof wearable patch-type ECG monitor powered by Samsung's Smart Health Processor, capable of continuous ECG recording for up to 14 days. The device feeds a companion mobile app (S-Patch App), a cloud-based physician reading platform (S-Patch Web), and an AI-powered ECG analysis service (S-Patch AI / ECG Lakehouse) trained on more than 6 billion labeled heartbeats from 790+ healthcare providers.

Product overview

Wellysis offers a unified S-Patch ECG monitoring solution consisting of wearable patch devices (S-Patch Wear - including Ex, ExL, and Cardio models), companion mobile apps (S-Patch App for patient and S-Patch Medi for healthcare providers), a cloud-based web analysis platform (S-Patch Web), and AI-powered analytics (S-Patch AI/ECG Lakehouse). The product suite enables end-to-end ECG testing: patients wear the lightweight patch for 1-14 days, data syncs via Bluetooth to mobile devices and uploads to cloud, AI algorithms perform initial analysis, and physicians review/edit reports via web portal. Upcoming BioArmour extends the platform to multi-biosignal monitoring for high-risk occupations.

Differentiator

Problem solved

Functional benefit

Brands

  • S-Patch: Flagship wearable ECG monitoring device line including S-Patch Ex (up to 3 days) and S-Patch ExL (up to 11-14 days) models, powered by Samsung Smart Health Processor.
  • S-Patch Web
  • S-Patch AI
  • BioArmour

Products and services

  • S-Patch Wear (Ex and ExL models) Wearable patch-type ECG monitoring device powered by Samsung Smart Health Processor. Two models: S-Patch Ex (up to 100 hours / 1–3 days) and S-Patch ExL (up to 264 hours / 3–11 days, FDA cleared for up to 14 days). Weighs 8.5–11g, IP55 waterproof, reusable with replaceable electrodes and coin-cell batteries, Bluetooth BLE 5.1 connectivity. Sold as a medical device prescribed by hospitals to clinics, hospitals, screening centers, CROs, and corporate wellness programs.
  • S-Patch App (Ex) Patient-facing mobile application (iOS and Android) paired with S-Patch Wear. Provides real-time ECG waveform display, live HR and HRV monitoring, symptom and activity diary, and automatic encrypted upload of ECG data to the cloud server upon test completion. Targets patients prescribed the S-Patch Ex wearable.
  • S-Patch App (Medi) Healthcare professional mobile application for managing S-Patch tests without requiring the patient's smartphone. Supports multiple simultaneous patient tests, device management, live ECG monitoring, battery level tracking, and scheduled data uploads. Used by clinicians and clinical staff in hospitals, clinics, and screening centers.
  • S-Patch Web Cloud-based ECG reading and analysis web platform for physicians and clinical staff. Features test management, ECG data review with AI pre-analysis, and report generation (Physician Report, Screening Report, Full Disclosure Report) delivered as PDF documents. Sold as a subscription/SaaS service to clinics, hospitals, and screening centers, with optional professional ECG analysis services.
  • S-Patch AI (ECG Lakehouse) AI-powered ECG analysis service backed by the ECG Lakehouse deep neural network platform trained on 6B+ labeled heartbeats from 1.5M+ hours of continuous ECG across 790+ healthcare providers. Capabilities include arrhythmia diagnosis, ECG clinical reports, HRV-based stress scoring, posture analysis, activity tracking, fall detection, and atrial fibrillation prediction. Delivered as an add-on analysis service for clinical customers and licensed to partner platforms (e.g., Medicalgorithmics DeepRhythmAI).
  • BioArmour Next-generation wearable solution for frontline responders (firefighters, police, military, coast guards) and high-performance athletes. AI-powered multi-biosignal analysis monitoring ECG, core body temperature, body composition, and motion for early detection of abnormal signs. Multiple form factors with high durability for high-risk frontline and athletic environments. Unveiled at CES 2026 and targeted at public safety agencies and defense organizations.

Quantifiable outcome

  • Detection rate increases to over 80% in 7 days vs 30% in 24 hours for traditional Holter
  • +2 more outcomes

Companies that use Wellysis

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Wellysis technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability6 records

Feature5 records

Wellysis partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and major.

  • Medicalgorithmics S.A.coreTechnology or Integration · 14 May 2025Strategic partnership with Poland-based AI-driven cardiac diagnostics company. Wellysis integrates FDA-cleared S-Patch with Medicalgorithmics' DeepRhythm Platform (DRP) and DeepRhythmAI (DRAI) algorithms for more precise, real-time patient data analysis. Expected to enhance product capabilities and support global customer expansion.
  • HeartcoR SolutionscoreChannel Partner/ Reseller/ Distributor · 28 April 2025Exclusive partnership for clinical trials. HeartcoR Solutions, a leading ECG core lab for pharmaceutical and medical device cardiac safety studies, has exclusive rights to offer S-Patch device in global clinical trials. Supports decentralized clinical trials with easy-to-use wearable ECG technology.
  • Artella SolutionscoreChannel Partner/ Reseller/ Distributor · 8 March 2024Partnership for US remote cardiac monitoring service launch. Artella provides comprehensive remote cardiac monitoring across 10 US states. Combined offering includes Samsung smartphones/smartwatches integration with S-Patch ExL. Starting in Texas with expansion plans.
  • Samsung ElectronicscoreStrategic or Co-development Partner · 15 November 2023Business collaboration with Samsung Electronics' System LSI division for next-generation S-Patch development. Joint development agreement for wearable biosignal measurement devices using Samsung's Smart Health Processor. Includes monitoring services for high-risk occupations and corporate wellness programs.
  • Kangbuk Samsung HospitalmajorStrategic or Co-development Partner · 20 October 2023Corporate cardiovascular disease prevention program with Kangbuk Samsung Hospital and Samsung Electronics. Provides full-covered health management services within workplace using S-Patch ECG tests for Samsung DS employees.
  • DozeecoreChannel Partner/ Reseller/ Distributor · 1 October 2023Partnership with India's prominent bed monitoring solutions provider. S-Patch devices to be integrated into 50,000 of Dozee's hospital beds starting January 2024, following successful product launch event in New Delhi.
  • Samjin Pharmaceutical Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 20 October 2020Exclusive distributor and investment contract. Samjin Pharmaceutical distributes S-Patch Cardio in Korean domestic market. Partnership enables wide distribution from primary care clinics to tertiary hospitals.
  • Stanford University School of MedicinemajorStrategic or Co-development Partner · 1 June 2020Research collaboration for COVID-19 wearable project monitoring recovered patients. Stanford uses S-Patch Cardio in project involving 1,000 recovered COVID-19 patients to study cardiovascular health impacts.
  • Apollo Hospitals (India)majorStrategic or Co-development Partner · 1 September 2019Joint development MOU signed for cardiac monitoring solutions. Apollo operates 40+ heart disease centers across India. Partnership for market expansion in India.

Scale indicators8 records

Recent moves9 records

Expansion highlights8 records

Wellysis competitors and assessment

Company assessment

Direct peers

  • Eko Health: Eko develops AI-powered digital stethoscopes with ECG and cardiac auscultation analysis, including SENSORA cardiac AI platform. Comparable to Wellysis in AI-driven cardiac diagnostics and expanding into multi-biosignal wearables for clinicians.
  • VivaLNK: VivaLNK makes wearable ECG patches and connected health sensors for remote patient monitoring. Direct comparable to S-Patch in form factor and continuous monitoring use cases, also serving clinical trial and RPM customers. (Also notable as the prior employer of Wellysis's CCO.)
  • Medicalgorithmics: Medicalgorithmics is a Poland-based cardiac diagnostics AI company offering DeepRhythm Platform (DRP) and DeepRhythmAI algorithms. Already a strategic integration partner of Wellysis, with overlapping AI ECG analysis capabilities and customer base in pharma clinical trials.
  • AliveCor: AliveCor's KardiaMobile is a single/6-lead ECG device for consumer and clinical AF detection, with AI-based interpretation. Competes with Wellysis in clinical-grade ECG AI and offers an alternative delivery model (handheld vs patch).
  • iRhythm Technologies: iRhythm is the leading US patch-based cardiac monitor (Zio) with strong CMS reimbursement and a deep clinical evidence base. Direct competitor to Wellysis's S-Patch in the ambulatory ECG monitoring segment, with overlap in arrhythmia detection AI and enterprise hospital sales motion.

Broad incumbents

  • Apple (Apple Watch ECG): Apple Watch offers single-lead ECG with FDA-cleared AF detection for consumer use. A broad incumbent shaping consumer expectations around wearable ECG and indirectly competing for cardiac monitoring mindshare, though limited to consumer/wrist-based form factor.
  • Boston Scientific (Preventice Solutions): Boston Scientific acquired Preventice Solutions, which offers BodyGuardian remote cardiac monitoring. A larger incumbent with established US sales infrastructure, deep reimbursement, and broader cardiology device portfolio competing for hospital accounts.
  • Philips (BioTelemetry): Philips acquired BioTelemetry, one of the largest US ambulatory cardiac monitoring providers (MCOT, Holter). A broad incumbent offering overlapping remote cardiac monitoring and AI analysis services to Wellysis's target hospital segment.

Emerging players

  • Dozee: Dozee is India's leading bed-based contactless patient monitoring company, integrating Wellysis S-Patch into 50,000 hospital beds. Comparable in remote patient monitoring for hospital inpatients, focused primarily on South Asia with growing international expansion.

Regional players

  • HeartcoR Solutions: HeartcoR is a US-based ECG core lab focused on cardiac safety studies for pharma and medical device clinical trials. Exclusive channel partner of Wellysis for clinical trials; comparable in cardiac clinical services but serving a different primary customer segment (CROs vs hospitals).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Wellysis social profiles

Digital presence

Wellysis compliance and trust

Trust signal

Compliance9 records

Wellysis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wellysis leadership team

Management profile

Number of profiles

Profiles6 records

Wellysis subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Wellysis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wellysis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellysis

What does Wellysis do?

Wellysis develops and sells the S-Patch, a lightweight (8.5–11g), reusable, waterproof wearable patch-type ECG monitor powered by Samsung's Smart Health Processor, capable of continuous ECG recording for up to 14 days. The device feeds a companion mobile app (S-Patch App), a cloud-based physician reading platform (S-Patch Web), and an AI-powered ECG analysis service (S-Patch AI / ECG Lakehouse) trained on more than 6 billion labeled heartbeats from 790+ healthcare providers.

Is Wellysis a public or private company?

Wellysis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Wellysis founded?

Wellysis was founded in 2019. It employs 11 to 50 people.

Where is Wellysis based?

Wellysis is headquartered in Seoul, South Korea, in the Asia region.

How does Wellysis make money?

Four revenue lines are on record. S-Patch Hardware Sales are the primary driver. The others are software/SaaS Subscriptions, analysis Services and AI Algorithm Licensing.

Who are Wellysis's main competitors?

Direct peers on record are Eko Health, VivaLNK, Medicalgorithmics, AliveCor and iRhythm Technologies. Broad incumbents are Apple (Apple Watch ECG), Boston Scientific (Preventice Solutions) and Philips (BioTelemetry). Dozee is listed as an emerging player. HeartcoR Solutions is listed as a regional player.

Does Wellysis have an API?

Yes. Wellysis offers SDK and API options for product integration. The inquiry form includes categories for 'SDK', 'API', and 'Inquiries' under product interest options, indicating availability for developers. Specific details on API type (REST, GraphQL, etc.), authentication methods, rate limits, versioning, or sandbox availability are not specified in the provided source material.

What industry is Wellysis in?

Wellysis's product category is Wearable ECG Monitoring Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MobiHealthNews510(k) for ECG AI, Chinese smart ring and more briefsWellysis received FDA 510(k) clearance for its ECG AI software, and Shenzhen Ninenovo got clearance for its smart ring's blood oxygen monitoring. Seoul St. Mary's Hospital developed an AI model to predict liver complications, and NTL Healthcare launched an on-premises cervical screening system.PR Newswire APACWellysis Secures FDA 510(k) Clearance for AI-Powered ECG Analysis Software, S-Patch CardioAIWellysis received FDA 510(k) clearance for its AI-powered ECG analysis software, S-Patch CardioAI, on September 25, 2026, as a Class II device. The clearance enables healthcare providers to integrate the software into web and mobile applications for remote patient monitoring. Wellysis plans to introduce CardioAI to existing S-Patch customers and expand to IDTFs, CROs, and RPM providers with subscription and per-test models.PR Newswire APACWellysis Secures FDA 510(k) Clearance for AI-Powered ECG Analysis Software, S-Patch CardioAIWellysis received FDA 510(k) clearance for its AI-powered ECG analysis software, S-Patch CardioAI, on September 25, 2026. The clearance allows integration into third-party ECG platforms and clinical workflows, with plans to introduce it to existing S-Patch customers and expand to IDTFs, CROs, and RPM providers. The company will support recurring subscription and per-test commercial models.HIT ConsultantAccurKardia and Wellysis Form Multi-Year Strategic Partnership to Deliver End-to-End Cardiac MonitoringAccurKardia, an ECG-led diagnostics software company, and Wellysis, a Samsung SDS spin-off, executed a multi-year strategic partnership agreement in Seoul to launch a turnkey cardiac monitoring solution in the United States. The alliance pairs Wellysis' S-Patch wearable ECG monitor with AccurKardia's cloud-based AccurECG 2.0 platform, an FDA-cleared Class II software as a medical device that delivers 99% accuracy across 13 arrhythmia classifications. The combined offering leverages Wellysis' global distribution network spanning over 2,000 active clinics and hospitals worldwide, building on initial system integrations completed in April 2025 and vendor approvals finalized in June 2025.Business Wire BlogAccurKardia and Wellysis Sign Multi-Year Agreement to Provide Wellysis’ Turnkey Cardiac Monitoring Offering in the U.S. MarketAccurKardia and Wellysis have signed a multi-year agreement in Seoul under which AccurKardia's AccurECG 2.0 FDA-cleared ECG analytics platform will power Wellysis' turnkey cardiac monitoring offering in the U.S. market. The partnership combines Wellysis' S-Patch wearable ECG device with automated analytics and reporting for Holter, extended Holter, and mobile cardiac telemetry workflows. The agreement builds on the companies' platform integration completed in April 2025 and marks AccurKardia's formal entry as an approved vendor to Wellysis in June 2025.FinancialContent Business PageAccurKardia and Wellysis Sign Multi-Year Agreement to Provide Wellysis’ Turnkey Cardiac Monitoring Offering in the U.S. MarketAccurKardia and Wellysis signed a multi-year agreement in Seoul last week, under which AccurKardia's FDA-cleared AccurECG 2.0 platform will serve as the analytics engine powering Wellysis' S-Patch wearable ECG device for the U.S. market. The combined offering integrates hardware, analytics, and reporting into a single workflow for cardiology and general medicine practices, covering Holter, extended Holter, and mobile cardiac telemetry workflows. The agreement builds on the companies' platform integration in April 2025 and represents Wellysis' expansion into the U.S. cardiac monitoring market.InnovationMapWellysis closes $13M pre-IPO roundWellysis, a wearable biosensing company, closed a $13.5 million pre-IPO round led by Korea Investment Partners and others. The funding brings total capital to about $30 million and will support the S-Patch MX, which captures over 30 biometric signals, and expand Houston operations. The company plans a Korea Securities Dealers Automated Quotations listing in Q4 2026 or Q1 2027.PR NewswireHeartcoR Solutions Announces Exclusive Partnership with Wellysis to Make the Wellysis S-Patch Wearable ECG Device Available to HeartcoR's Clinical Trial PartnersHeartcoR Solutions announced an exclusive partnership with Wellysis to offer the Wellysis S-Patch wearable ECG device in global cardiac safety trials. The FDA-cleared device operates for up to 14 days on a single charge and is designed for remote monitoring. The collaboration aims to improve trial outcomes by providing easy-to-use remote monitoring.YahooWellysis and Artella Solutions Launch Innovative Remote Cardiac Monitoring Service in the US.Wellysis and Artella Solutions launched a remote cardiac monitoring service in the US, starting in Texas. The service uses the FDA-cleared S-Patch ExL device, which offers 14-day battery life, and includes bundled Samsung smartphones and smartwatches. The partnership will be unveiled at the ACC meeting in April, with AI algorithm clearance pending.PR NewswireWellysis and Artella Solutions Launch Innovative Remote Cardiac Monitoring Service in the US.Wellysis and Artella Solutions launched a remote cardiac monitoring service in the US, starting in Texas. The service uses the FDA-cleared S-Patch ExL device, which offers 14-day battery life, and bundles Samsung smartphones and smartwatches. The partnership will be unveiled at the ACC meeting in April, with AI algorithm FDA clearance pending.